Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis
- 25 February 2017
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 32 (8) , 1451-1456
Abstract
Background Patients who develop sickle cell disease (SCD) nephropathy are at a high risk for mortality. The pathophysiology of vaso-occlusive pain crisis may contribute to acute kidney injury (AKI). Non-steroidal anti-inflammatory drugs, known inducers of AKI, are used to treat pain crises. Multiple gaps exist in the knowledge about the impact of AKI in SCD. Methods We conducted a 2-year retrospective review of AKI events in patients admitted for vaso-occlusive crisis. AKI was defined by an increase of ≥0.3 mg/dL or 50% in serum creatinine from baseline. Laboratory values and ketorolac administration by days and dose (mg/kg) were identified from hospital records. A generalized mixed effects model for binary outcomes evaluated AKI based on laboratory variables and ketorolac administration. A generalized mixed Poisson effects model analyzed the association of AKI with hospital length of stay. Results Thirty-three out of 197 admissions for vaso-occlusive pain crisis (17%) were associated with AKI. Fifty-two percent of the cases presented to the Emergency Room (ER) with AKI. Every one unit decrease in hemoglobin from baseline to admission increased the risk of AKI by 49%. Among patients who received ketorolac for pain, both total days and doses of ketorolac were associated with AKI. Finally, patients with pain and AKI required longer periods of hospitalization than patients without AKI. Conclusion Acute kidney injury during sickle cell pain crisis is common and may be an important modifiable risk factor for developing chronic kidney disease (CKD). Further studies are needed to determine the impact of nephrotoxic medications on progressive SCD nephropathy.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (K23HL127100)
- American Society of Hematology (Scholar Award)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK079337)
This publication has 40 references indexed in Scilit:
- Interleukin-19 Mediates Tissue Damage in Murine Ischemic Acute Kidney InjuryPLOS ONE, 2013
- High one year mortality in adults with sickle cell disease and end‐stage renal diseaseBritish Journal of Haematology, 2012
- Kidney function decline after a non-dialysis-requiring acute kidney injury is associated with higher long-term mortality in critically ill survivorsCritical Care, 2012
- Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress responseFree Radical Biology and Medicine, 2011
- Hemolysis and Acute Kidney FailureAmerican Journal of Kidney Diseases, 2010
- Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse modelHaematologica, 2010
- Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell diseaseAmerican Journal of Physiology-Renal Physiology, 2010
- The endothelial cell in ischemic acute kidney injury: implications for acute and chronic functionKidney International, 2007
- Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survivalClinical Nephrology, 2002
- Ketorolac-induced irreversible renal failure in sickle cell disease: a case reportPediatric Nephrology, 1999